Twist Bioscience Co. (NASDAQ:TWST) Receives $51.90 Average Price Target from Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have earned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $51.90.

A number of research firms have commented on TWST. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Barclays dropped their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Evercore ISI upped their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Robert W. Baird lifted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th.

Insider Activity at Twist Bioscience

In related news, SVP Paula Green sold 1,057 shares of the company’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92. Following the transaction, the senior vice president now owns 121,013 shares of the company’s stock, valued at $5,029,300.28. This represents a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Robert F. Werner sold 1,448 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total transaction of $64,580.80. Following the sale, the chief accounting officer now owns 45,620 shares in the company, valued at $2,034,652. The trade was a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 83,754 shares of company stock worth $3,869,144 in the last 90 days. 3.92% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TWST. Thrivent Financial for Lutherans acquired a new stake in shares of Twist Bioscience during the 3rd quarter worth about $43,992,000. Point72 Asset Management L.P. boosted its position in Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC raised its holdings in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after buying an additional 575,080 shares during the period. State Street Corp boosted its stake in shares of Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the period. Finally, Wellington Management Group LLP increased its position in shares of Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after acquiring an additional 521,272 shares during the last quarter.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $43.60 on Wednesday. Twist Bioscience has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The firm has a market capitalization of $2.59 billion, a P/E ratio of -12.11 and a beta of 1.85. The stock’s fifty day moving average is $46.35 and its two-hundred day moving average is $46.46.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.